STOCKHOLM, Sweden, Nov. 29, 2013 (GLOBE NEWSWIRE) -- The total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi) as per 29 November 2013 amounts to 270,389,770 shares, all common shares, corresponding to in total 270,389,770 votes. The increase in the number of common shares and votes results from a conversion of all 5,163,172 class C shares held by the company into common shares. The shares are intended to ensure fulfillment of commitments under incentive programs.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
For more information - not for publication
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
The above information has been made public in accordance with the Financial Instruments Trading Act. The information was released for public distribution on 29 November 2013 at 08:00 CET.
New number of shares and votes in Swedish Orphan Biovitrum AB (publ): http://hugin.info/134557/R/1746473/587932.pdf